Cytokinetics Q1 2022 Earnings Report
Key Takeaways
Cytokinetics reported a net loss of $89.4 million, or $1.05 per share, for the first quarter of 2022. Cash, cash equivalents and investments totaled $686.1 million at March 31, 2022.
NDA for omecamtiv mecarbil was accepted and filed with FDA.
SEQUOIA-HCM and Cohort 4 of REDWOOD-HCM opened to enrollment.
Positive data from Cohort 3 of REDWOOD-HCM demonstrated a substantial treatment effect with aficamten in patients taking disopyramide.
Data from GALACTIC-HF reinforced its safety, ease of initiation in the hospital setting and potential to reduce costs associated with fewer hospitalizations.
Cytokinetics
Cytokinetics
Forward Guidance
The press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties.